Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC) (2022) Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, et al. Conference contribution Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study) (2022) Zeuschner P, Hoelters S, Stoeckle M, Seliger B, Mueller A, Bachmann HS, Gruenwald V, et al. Conference contribution Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT (2022) Goebell P, Gruellich C, Mueller L, Boegemann M, Martens U, Von Der Heyde E, Reichert D, et al. Conference contribution Early CRP kinetics predict long-term treatment success and favorable outcomes of anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma (2022) Kluemper N, Sikic D, Saal J, Buettner T, Jarczyk J, Zeuschner P, Weinke M, et al. Conference contribution Updated analysis of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma with induction chemoimmunotherapy followed by radioimmunotherapy (2022) Hecht M, Eckstein M, Kallies A, Von Der Grun J, Illmer T, Klautke G, Laban S, et al. Conference contribution A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (Everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study of the IAG-N) (2022) Hilser T, Gruenwald V, Bergmann L, Goebell P, Strauss A, Meiler J, Hartmann A, et al. Conference contribution Prognostic potential of baseline HRQoL in advanced and metastatic renal cell carcinoma (2022) Gruenwald V, Goebell P, Schostak M, Welslau M, Doehn C, Degenkolbe E, Ehness R, et al. Conference contribution Clinical and histopathological characterization of penile carcinomas with focus on HPV-status and histological subtype (2022) Mink J, Khalmurzaev O, Hoelters S, Pryalukhin A, Heinzelbecker J, Lohse S, Bende K, et al. Conference contribution Multicentric validation of a comprehensive geriatric assessment to predict functional outcome and mortality following urooncological operations (2022) Fiebig C, Kahlmeyer A, Bannert H, Taubert H, Wach S, Koneval L, Graf S, et al. Conference contribution